This finding appeared to be consistent with findings from a trial study in which TAK-228, a TORC1/2 inhibitor, demonstrated superior therapy efficacy in NFE2L2-mutated LUSC compared to KEAP1-mutated LUSC, KRAS/NFE2L2- or KEAP1-mutated NSCLC, despite the fact that the majority of patients received platinum-based chemotherapy and immunotherapy [73]. Here, NFE2L2 is linked to non-small cell lung carcinoma.